Company: STAA
Filing Date: 2025-10-30
Form Type: DEFA14A
Source: 0001193125-25-258558
Chunk: 11

Company: STAAR SURGICAL CO
Filing Date: 2025-10-30
Form: DEFA14A
Chunk 11
---
; |

| • |     | extensive clinical trials and resources devoted to research and development; |

| • |     | changes in pricing and pricing controls; |

| • |     | compliance with and changes to applicable laws and regulations, including laws pertaining to healthcare fraud and 
 abuse, and U.S. Food and Drug Administration or international regulations related to product approval; and        |

| • |     | the discretion of regulatory agencies to approve or reject existing, new or improved products, or to require 
 additional actions before or after approval, or to take enforcement action.                                  |

8

Additional information and detailed discussion of these risks, uncertainties and other
potential factors that could affect STAAR’s business and performance and cause actual results or outcomes to differ materially from the results, performance or achievements addressed in STAAR’s forward-looking statements is included in
STAAR’s other filings with the SEC, including in the section of this proxy statement titled “Risk Factors” and sections titled “Risk Factors” and “Management’s Discussion and Analysis of
Financial Condition and Results of Operations” of STAAR’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent
filings. STAAR assumes no obligation to update its forward-looking statements, which speak as of their respective dates, whether as a result of new information, future events or otherwise.

The first paragraph of the risk factor that begins with the heading, “The consummation of the Merger is subject to certain closing conditions…” on pages 23-24of the proxy statement is hereby amended and supplemented as follows:

The obligations of STAAR, Alcon and Merger Sub to consummate the transactions contemplated by the Merger Agreement are subject to the
satisfaction or waiver of a number of conditions, including the adoption of the Merger Agreement by holders of a majority of the outstanding shares of STAAR common stock entitled to vote thereon. Ownership of STAAR common stock is currently
concentrated among a few stockholders, and STAAR’s largest stockholder, Broadwood Partners, L.P. (“Broadwood”), reported beneficial ownership as of August 8, 2025 of approximately 27.3% of STAAR’s outstanding shares of
STAAR common stock. On September 2, 2025, Broadwood filed a Schedule 13D/A and issued a related press release indicating, among other things, that it intends to vote against the Merger Proposal. On September 1524, 2025, Broadwood and other members of